Top

04-07-2013 | Cancer pain | Book chapter | Article

5. Mechanisms in Cancer Pain

Authors: Jerzy Wordliczek, MD, PhD, Renata Zajaczkowska, MD, PhD

Publisher: Springer London

Abstract

Pain in the cancer patient is caused primarily by the development of the disease process (tumours, metastases), which in turn causes, amongst other things, infiltration of soft tissues, bones, nervous system structures, and serous membranes. Cancer may also cause necrosis of solid organs or induce the occlusion of blood vessels.

In addition, pain in the cancer patient may be the consequence of anticancer therapy, which, in the case of radiation therapy, may lead to the development of post-radiation plexopathies or myelopathies. In the case of chemotherapy, related pain syndromes and peripheral neuropathy are the common adverse events of a number of anticancer medications. Surgically treated patients, especially those following thoracotomy, mastectomy, or amputation, may develop persistent postoperative pain (postsurgical neuropathy).

An important kind of pain in cancer patients is acute pain associated with cancer pain treatment, which is due to both diagnostic (i.e., biopsies, blood samples) and therapeutic procedures (acute postoperative pain).

Lastly, the pain in question may be due to mechanisms unrelated to the cancer itself or its treatment, e.g., chronic headache, low-back pain, and pain that the patient may have suffered prior to the diagnosis of cancer.

Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. Mol Interv. 2010;10(3):164–78.PubMedCrossRef

Fitzgibbon DR, Chapman CR. Cancer pain: assessment and diagnosis. In: Loeser JD, Butler SH, Chapman CR, Turk DC, editors. Bonica’s management of pain. Philadelphia: Lippincott Williams &Wilkins; 2001. p. 623–58.

Urch CE. Pathophysiology of cancer pain. In: Walsh D, editor. Palliative medicine. Philadelphia: Saunders Elsevier; 2009. p. 1378–84.CrossRef

Gold MS, Gebhart GF. Peripheral pain mechanisms and nociceptor sensitization. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica’s management of pain. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 24–34.

Stein C, Clark JD, Uhtaek O, Vasko MR, Wilcox GL, Overland AC, et al. Peripheral mechanisms of pain and analgesia. Brain Res Rev. 2009;60(1):90–113.PubMedCrossRef

Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–84.PubMedCrossRef

Meyer RA, Ringkamp M, Campbell JN, Raja SN. Peripheral mechanisms of cutaneous nociception. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack’s textbook of pain. Philadelphia: Elsevier; 2008. p. 3–34.

Friedman WJ, Greene LA. Neurotrophin signaling via Trks and p75. Exp Cell Res. 1999;253(1):131–42.PubMedCrossRef

Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem. 2001;276(21):17864–70.PubMedCrossRef

10.

Geldof AA, Van Haarst EP, Newling DW. Neurotrophic factors in prostate and prostatic cancer. Prostate Cancer Prostatic Dis. 1998;1(5):236–41.PubMedCrossRef

11.

Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002;36(1):57–68.PubMedCrossRef

12.

Mamet J, Baron A, Lazdunski M, Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci. 2002;22:10662–70.PubMed

13.

Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α. Br J Pharmacol. 1997;121(3):417–24.PubMedCrossRef

14.

Constantin CE, Mair N, Sailer CA, Andratsch M, Xu ZZ, Blumer MJ, et al. Endogenous tumor necrosis factor α (TNFα) requires TNF receptor type 2 to generate heat hyperalgesia in mouse cancer model. J Neurosci. 2008;28:5072–81.PubMedCrossRef

15.

Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427–35.PubMedCrossRef

16.

Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–10.PubMedCrossRef

17.

DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol. 2004;164(4):1131–9.PubMedCrossRef

18.

Hoogerwerf WA, Zou L, Shenoy M, Sun D, Micci MA, Lee-Hellmich H, et al. The proteinase-activated receptor 2 is involved in nociception. J Neurosci. 2001;21:9036–42.PubMed

19.

Alier KA, Endicott JA, Stemkowski PL, Cenac N, Cellars L, Chapman K, et al. Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther. 2008;324:224–33.PubMedCrossRef

20.

Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6:151–8.PubMedCrossRef

21.

Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, et al. Protease-activated receptor2 sensitizes TRPV1 by protein kinase Cε- and A-dependent mechanisms in rats and mice. J Physiol. 2006;575(2):555–71.PubMedCrossRef

22.

Grant AD, Cottrell GS, Amadesi S, Trevisani M, Nicoletti P, Materazzi S, et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol. 2007;578(3):715–33.PubMedCrossRef

23.

Lam DK, Schmidt BL. Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain. 2010;149(2):263–72.PubMedCrossRef

24.

McMahon SB. Mechanisms of sympathetic pain. Br Med Bull. 1991;47(3):584–600.PubMed

25.

Mercadante S. Pathophysiology of chronic pain. In: Bruera E, Higginson IJ, Ripamonti C, von Gunten C, editors. Textbook of palliative medicine. London: Edward Arnold; 2006. p. 359–66.

26.

Erin D, Milligan L, Watkins R. Pathological and protective roles of glia in chronic pain. Nat Rev. 2009;10:23–36.CrossRef

27.

O’Callaghan JP, Miller DB. Spinal glia and chronic pain. Metabolism. 2010;59 Suppl 1:21–6.CrossRef

28.

Khasabov SG, Hamamoto DT, Harding-Rose C, Simone DA. Tumor-evoked hyperalgesia and sensitization of nociceptive dorsal horn neurons in a murine model of cancer pain. Brain Res. 2007;1180:7–19.PubMedCrossRef

29.

Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450–5.PubMedCrossRef

30.

Randich A, Ness T. Modulation of spinal nociceptive processing. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica’s management of pain. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 48–60.

31.

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243–9.CrossRef

32.

Middlemiss T, Laird BJA, Fallon MT. Mechanisms of cancer-induced bone pain. Clin Oncol. 2011;23:387–92.CrossRef

33.

Sabino MA, Mantyh PW. Pathophysiology of bone cancer pain. J Support Oncol. 2005;3(1):15–24.PubMed

34.

Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW. Bone cancer pain. Ann N Y Acad Sci. 2010;1198:173–81.PubMedCrossRef

35.

Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F, et al. Pain syndromes in haematological malignancies: an overview. Hematol J. 2004;5:293–303.PubMedCrossRef

36.

Niscola P, Tendas A, Scaramucci L, Giovaninni M, Cupelli L, De Sanctis V, et al. Pain in malignant hematology. Expert Rev Hematol. 2011;4(1):81–93.PubMedCrossRef

37.

Reddy SK. Causes and mechanisms of pain in palliative care patients. In: Bruera E, Higginson IJ, Ripamonti C, von Gunten C, editors. Textbook of palliative medicine. London: Edward Arnold; 2009. p. 368–79.

38.

Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19:92–101.PubMed

39.

Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.PubMedCrossRef

40.

Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010;12(6):215. http://breast-cancer-research.com/content/12/6/215,10.1186/bcr2781.PubMedCrossRef

41.

Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006;12:6305–8.CrossRef

42.

Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7:797–809.PubMedCrossRef

43.

Von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer. 2008;16:1105–15.CrossRef

44.

Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011;48:100–5.PubMedCrossRef

45.

Halvorson KG, Sevcik MA, Ghilardi JR, Rosol TJ, Mantyh PW. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain. 2006;22:587–600.PubMedCrossRef

46.

Nagae M, Hiraga T, Wakabayashi H, Wang L, Iwata K, Yoneda T. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone. 2006;39:1107–15.PubMedCrossRef

47.

Ghilardi JR, Röhrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci. 2005;25:3126–31.PubMedCrossRef

48.

Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.PubMedCrossRef

49.

Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, et al. Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain. 2007;11:406–14.PubMedCrossRef

50.

Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci. 2006;29:507–38.PubMedCrossRef

51.

Abraham J, Ross E, Klickovich RJ. Cancer-related visceral pain. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica’s management of pain. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 635–44.

52.

Larauche M, Mulak A, Taché Y. Stress and visceral pain: from animal models to clinical therapies. Exp Neurol. 2012;233:49–67.PubMedCrossRef

53.

Ceyhan GO, Michalski CW, Demir IE, Muller MW, Friess H. Pancreatic pain. Best Pract Res Clin Gastroenterol. 2008;22(1):31–44.PubMedCrossRef

54.

Hirai I, Kimura W, Ozawa K, Kudo S, Suto K, Kuzu H, et al. Perineural invasion in pancreatic cancer. Pancreas. 2002;24:15–25.PubMedCrossRef

55.

Marchesi F, Piemonti L, Mantovani A, Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev. 2010;21:77–82.PubMedCrossRef

56.

Twycross R. Cancer pain syndromes. In: Rice ASC, Warfield CA, Justins D, Eccleston C, editors. Cancer pain. London: Arnold; 2003. p. 3–19.

57.

Manfredi PI, Gonzales GR, Sady R, Chandler S, Payne R. Neuropathic pain in patients with cancer. J Palliat Care. 2003;19:115–8.PubMed

58.

Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.PubMedCrossRef

59.

Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. Pain. 2012;153:359–65.PubMedCrossRef

60.

Andrea M, Harriott BS, Gold MS. Contribution of primary afferent channels to neuropathic pain. Curr Pain Headache Rep. 2009;13:197–207.CrossRef

61.

Xua Q, Yaksh TL. A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Curr Opin Anaesthesiol. 2011;24:400–7.CrossRef

62.

Chung K, Lee BH, Yoon YW, Chung JM. Sympathetic sprouting in the dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain model. J Comp Neurol. 1996;376:241–51.PubMedCrossRef

63.

Lanteri-Minet M. Physiopathology of neuropathic pain syndromes. Therapie. 1999;54(1):117–20.PubMed

64.

Chien SQ, Li C, Li H, Xie W, Zhang JM. Sympathetic fiber sprouting in chronically compressed dorsal root ganglia without peripheral axotomy. J Neuropathic Pain Symptom Palliation. 2005;1(1):19–23.PubMed

65.

Dib-Hajj SD, Binshtok AM, Cummins TR, Jarvis MF, Samad T, Zimmermann K. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev. 2009;60(1):65–83.PubMedCrossRef

66.

Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep. 2008;60(3):297–307.PubMed

67.

Leung L, Cahill CM. TNF-α and neuropathic pain – a review. J Neuroinflammation. 2010;7(27):1–11.

68.

Gao YJ, Ji RR. Chemokines, neuronal–glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56–68.PubMedCrossRef

69.

Dickinson BD, Head CA, Gitlow S, Osbahr AJ. Maldynia: pathophysiology and management of neuropathic and maladaptive pain – a report of the AMA Council on Science and Public Health. Pain Med. 2010;11(11):1635–53.PubMedCrossRef

70.

Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992;355:75–8.PubMedCrossRef

71.

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–19.PubMedCrossRef

72.

Law M. Neurological complications. Cancer Imaging. 2009;9(Spec No A):71–4.CrossRef

73.

Blaes F, Tschernatsch M. Paraneoplastic neurological disorders. Expert Rev Neurother. 2010;10(10):1559–68.PubMedCrossRef

74.

Storstein A, Vedeler CA. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem. 2007;44:143–85.PubMedCrossRef

75.

Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2:22. http://www.OJRD.com/content/2/1/22.PubMedCrossRef

76.

Plantone D, Caliandro P, Iorio R, Frisullo G, Nociti V, Patanella AK, et al. Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer. J Neurol. 2011;258(5):921–2.PubMedCrossRef

77.

Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol. 2008;201–202:159–62.PubMedCrossRef

78.

Danko K, Ponyi A, Molnar AP, Andras C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol. 2009;21(6):594–8.PubMedCrossRef

79.

Moris G, Perez-Pena M, Miranda E, Lopez Anglada J, Ribacoba R, Gonzalez C. Trigeminal mononeuropathy: first clinical manifestation of breast cancer. Eur Neurol. 2005;54(4):212–3.PubMedCrossRef

80.

Van Horn A, Chamberlain MC. Neoplastic meningitis. J Support Oncol. 2012;10(2):45–53.PubMedCrossRef

81.

Chamberlain MC. Neoplastic meningitis. Oncologist. 2008;13(9):967–77.PubMedCrossRef

82.

Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103–19.PubMedCrossRef

83.

Ostgathe C, Voltz R. Brain metastases. In: Walsh D, editor. Palliative medicine. Philadelphia: Saunders-Elsevier; 2009. p. 1240–4.CrossRef

84.

Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23:2028–37.PubMedCrossRef

85.

Maranzano E, Trippa F, Chirico L, Basagni ML, Rossi R. Management of metastatic spinal cord compression. Tumori. 2003;89(5):469–75.PubMed

86.

Sciubba DM, Gokaslan ZL. Diagnosis and management of metastatic spine disease. Surg Oncol. 2006;15:141–51.PubMedCrossRef

87.

Ribas ES, Schiff D. Spinal cord compression. Curr Treat Options Neurol. 2012;14(4):391–401.PubMedCrossRef

88.

Janjan N, Lin E, McCutcheon I, Perkins G, Das P, Krishnan S, et al. Vertebral metastases and spinal cord compression. In: Walsh D, editor. Palliative medicine. Philadelphia: Saunders-Elsevier; 2009. p. 1247–60.CrossRef

89.

Griffo Y, Obbens EA. Neurological complications. In: Walsh D, editor. Palliative medicine. Philadelphia: Saunders-Elsevier; 2009. p. 1237–40.CrossRef

90.

Vecht CJ, Hoff AM, Kansen PJ, de Boer MF, Bosch DA. Types and causes of pain in cancer of the head and neck. Cancer. 1992;70(1):178–84.PubMedCrossRef

91.

Amato AA, Collins MP. Neuropathies associated with malignancy. Semin Neurol. 1998;18(1):125–44.PubMedCrossRef

92.

Jaeckle KA. Neurologic manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. 2010;30(3):254–62.PubMedCrossRef

93.

Iyer VR, Sanghvi DA, Merchant N. Malignant brachial plexopathy: a pictorial essay of MRI findings. Indian J Radiol Imaging. 2010;20(4):274–8.PubMedCrossRef

94.

Rigor BM. Pelvic cancer pain. J Surg Oncol. 2000;75(4):280–300.PubMedCrossRef

95.

Landha SS, Spinner RJ, Suarez GA, Amrami KK, Dyck PJ. Neoplastic lumbosacral radiculoplexopathy in prostate cancer by direct perineural spread: an unusual entity. Muscle Nerve. 2006;34(5):659–65.CrossRef

96.

Hébert-Blouin MN, Amrami KK, Myers RP, Hanna AS, Spinner RJ. Adenocarcinoma of the prostate involving the lumbosacral plexus: MRI evidence to support direct perineural spread. Acta Neurochir. 2010;152(9):1567–76.PubMedCrossRef

97.

Marskey H, Bogduk K. Descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press; 1994.

98.

Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth. 2008;101(1):77–86.PubMedCrossRef

99.

Hinrichs-Rocker A, Schulz K, Jarvinen I, Lefering R, Simanski C, Neugebauer EA. Psychosocial predictors and correlates for chronic post-surgical pain (CPSP) – a systematic review. Eur J Pain. 2009;13(7):719–30.PubMedCrossRef

100.

Niraj G, Rowbotham DJ. Persistent postoperative pain: where are we now? Br J Anaesth. 2011;107(1):25–9.PubMedCrossRef

101.

Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367(9522):1618–25.PubMedCrossRef

102.

Aasvang EK, Gmaehle E, Hansen JB, Gmaehle B, Forman JL, Schwarz J, et al. Predictive risk factors for persistent postherniotomy pain. Anesthesiology. 2010;112(4):957–69.PubMedCrossRef

103.

Fitzgibbon DR. Mechanisms, assessment, and diagnosis of pain due to cancer. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica’s management of pain. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 559–82.

104.

Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008;99(4):604–10.PubMedCrossRef

105.

Junga BF, Ahrendt M, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003;104(1–2):1–13.CrossRef

106.

Hansen DM, Kehlet H, Gärtner R. Phantom breast sensations are frequent after mastectomy. Dan Med Bull. 2011;58(4):A4259.PubMed

107.

Vadivelu N, Schreck M, Lopez J, Kodumudi G, Narayan D. Pain after mastectomy and breast reconstruction. Am Surg. 2008;74(4):285–96.PubMed

108.

Björkman B, Arnér S, Hydén LC. Phantom breast and other syndromes after mastectomy: eight breast cancer patients describe their experiences over time: a 2-year follow-up study. J Pain. 2008;9(11):1018–25.PubMedCrossRef

109.

Dijkstra PU, Rietman JS, Geertzen JH. Phantom breast sensations and phantom breast pain: a 2-year prospective study and a methodological analysis of literature. Eur J Pain. 2007;11(1):99–108.PubMedCrossRef

110.

Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005;92(2):225–30.PubMed

111.

Ovesen P, Krøner K, Ornsholt J, Bach K. Phantom-related phenomena after rectal amputation: prevalence and clinical characteristics. Pain. 1991;44(3):289–91.PubMedCrossRef

112.

Probstner D, Thuler LC, Ishikawa NM, Alvarenga RM. Phantom limb phenomena in cancer amputees. Pain Pract. 2010;10(3):249–56.PubMedCrossRef

113.

Hanley MA, Jensen MP, Smith DG, Ehde DM, Edwards WT, Robinson LR. Preamputation pain and acute pain predict chronic pain after lower extremity amputation. J Pain. 2007;8(2):102–9.PubMedCrossRef

114.

Rinne ML, Lee EQ, Wen PY. Central nervous system complications of cancer therapy. J Support Oncol. 2012;10(4):133–41.PubMedCrossRef

115.

Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.PubMedCrossRef

116.

Chamberlain MC. Neurotoxicity of cancer treatment. Curr Oncol Rep. 2010;12(1):60–7.PubMedCrossRef

117.

Dropcho EJ. Neurotoxicity of radiation therapy. Neurol Clin. 2010;28(1):217–34.PubMedCrossRef

118.

Westbury CB, Yarnold JR. Radiation fibrosis – current clinical and therapeutic perspectives. Clin Oncol (R Coll Radiol). 2012;24(10):657–72.CrossRef

119.

Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. J Reconstr Microsurg. 2004;20(2):149–52.PubMedCrossRef

120.

Chen AM, Hall WH, Li J, Beckett L, Farwell DG, Lau DH, et al. Brachial plexus-associated neuropathy after high-dose radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):165–9.PubMedCrossRef

121.

Gosk J, Rutowski R, Reichert P, Rabczyński J. Radiation-induced brachial plexus neuropathy – aetiopathogenesis, risk factors, differential diagnostics, symptoms and treatment. Folia Neuropathol. 2007;45(1):26–30.PubMed

122.

Dahele M, Davey P, Reingold S, Shun WC. Radiation-induced lumbo-sacral plexopathy (RILSP): an important enigma. Clin Oncol (R Coll Radiol). 2006;18(5):427–8.CrossRef

123.

Sanguineti G, Sormani MP, Marur S, Gunn GB, Rao N, Cianchetti M, et al. Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):235–42.PubMedCrossRef

124.

Rodríguez ML, Martín MM, Padellano LC, Palomo AM, Puebla YI. Gastrointestinal toxicity associated to radiation therapy. Clin Transl Oncol. 2010;12(8):554–61.PubMedCrossRef

125.

Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1–3):1–9.PubMedCrossRef

126.

Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care. 2011;5(1):1–7.PubMedCrossRef

127.

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–15.PubMedCrossRef

128.

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;8:573–84.CrossRef

129.

Pasetto LM, D′Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006;59(2):159–68.PubMedCrossRef

130.

Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109(1–2):132–42.PubMedCrossRef

131.

Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (TAXOL). Semin Oncol. 1993;20(4 Suppl 3):1–15.PubMed

132.

Niscola P, Tendas A, Scaramucci L, Giovannini M, De Sanctis V. Pain in blood cancers. Indian J Palliat Care. 2011;17(3):175–83.PubMedCrossRef

133.

Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283–95.PubMedCrossRef

134.

Niscola P, Romani C, Scaramucci L, Dentamaro T, Cupelli L, Tendas A, et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant. 2008;41(9):757–64.PubMedCrossRef

135.

Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218:47–54.PubMedCrossRef

136.

Sweeney MP, Bagg J. The mouth and palliative care. Am J Hosp Palliat Care. 2000;17(2):118–24.PubMedCrossRef

137.

Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR, et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer. 2003;98(2):406–12.PubMedCrossRef

138.

Niscola P. Mucositis in malignant hematology. Expert Rev Hematol. 2010;3(1):57–65.PubMedCrossRef

139.

Flores-Calderón J, Exiga-Gonzaléz E, Morán-Villota S, Martín-Trejo J, Yamamoto-Nagano A. Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase. J Pediatr Hematol Oncol. 2009;31(10):790–3.PubMedCrossRef

140.

Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44:1–26.CrossRef

141.

Miaskowski C, Cleary J, Burney R, Coyne P, Finley R, Forter R, et al. Guide line for the management of cancer pain in adults and children. Glenview: American Pain Society; 2005.

142.

Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011;25(2):185–98.PubMedCrossRef

143.

Torres Lacomba M, Mayoral del Moral O, Coperias Zazo JL, Gerwin RD, Goni AZ. Incidence of myofascial pain syndrome in breast cancer surgery: a prospective study. Clin J Pain. 2010;26:320–5.PubMedCrossRef

144.

Alvarez P, Ferrari LF, Levine JD. Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy. Ann Neurol. 2011;70(1):101–9.PubMedCrossRef

145.

Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005;19(5):651–8.

146.

Langemo D. General principles and approaches to wound prevention and care at end of life: an overview. Ostomy Wound Manage. 2012;58:24–34.PubMed

147.

Stephen-Haynes J. Pressure ulceration and palliative care: prevention, treatment, policy and outcomes. Int J Palliat Nurs. 2012;18:9–16.PubMed

Medicine Matters Oncology

Abstract